Feb. 5 (Bloomberg) -- Novartis AG is building a financial war chest with a $5 billion bond sale that could be used for acquisitions that the Swiss drugmaker is seeking to replace products facing generic competition.
Feb. 5 (Bloomberg) -- Novartis AG is building a financial war chest with a $5 billion bond sale that could be used for acquisitions that the Swiss drugmaker is seeking to replace products facing generic competition.
